Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TSHR | P16473 | 3/20 | 0.89 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.89 |
| ▸ | CA5A | P35218 | 2/20 | 0.50 |
| ▸ | CA5B | Q9Y2D0 | 2/20 | 0.50 |
| ▸ | CA2 | P00918 | 2/20 | 0.46 |
| ▸ | CA1 | P00915 | 1/20 | 0.42 |
| ▸ | NT5E | P21589 | 1/20 | 0.42 |
| ▸ | CA4 | P22748 | 1/20 | 0.42 |
| ▸ | CA6 | P23280 | 1/20 | 0.42 |
| ▸ | CA7 | P43166 | 1/20 | 0.42 |
| ▸ | CA9 | Q16790 | 1/20 | 0.42 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.39 |
| ▸ | MEN1 | O00255 | 1/20 | 0.39 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.39 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.32 |
| ▸ | BLM | P54132 | 1/20 | 0.31 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL28677037 | 1.00 | — | — | |
| SCHEMBL29818845 | 0.94 | TSHR (1.00) | TSHRTDP1CA5ACA5BCA2 | |
| SCHEMBL1938 | 0.94 | — | — | |
| SCHEMBL8379533 | 0.89 | — | — | |
| SCHEMBL7249115 | 0.89 | — | — | |
| SCHEMBL3422882 | 0.89 | TSHR (0.89) | TSHRTDP1CA5ACA5BCA2 | |
| SCHEMBL6223954 | 0.89 | — | — | |
| Lithium SCHEMBL929003 | 0.89 | TSHR (0.89) | TSHRTDP1CA5ACA5BCA2 | |
| SCHEMBL8378129 | 0.89 | — | — | |
| SCHEMBL9193935 | 0.89 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090326229-A1 | ALPHA-CARBOLINE DERIVATIVES AND METHODS FOR PREPARATION THEREOF | TAKEDA PHAMACEUTICAL COMPANY LIMITED (JP) | 2009-12-31 | — | — | US | disclosed |
| EP-2049535-A1 | ALPHA-CARBOLINE DERIVATIVES AND METHODS FOR PREPARATION THEREOF | Takeda Pharmaceutical Company Limited (JP) | 2009-04-22 | — | — | EP | disclosed |
| WO-2008016184-A1 | ALPHA-CARBOLINE DERIVATIVES AND METHODS FOR PREPARATION THEREOF | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2008-02-07 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090326229-A1 | ALPHA-CARBOLINE DERIVATIVES AND METHODS FOR PREPARATION THEREOF | XDH, F7, CYP4X1 | TSHR 3654/4885TDP1 3025/4885CA5A 126/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.